Sacubitril (INN developmental code name AHU-377) is an antihypertensive drug used in combination with valsartan. The combination drug valsartan/sacubitril, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. It was approved under the FDA's priority review process for use in heart failure on July 7, 2015.

CAS：149709-62-6
中文别名：沙库必曲;4-(((2S,4R)-1-([1,1\'-联苯]-4-基)-5-乙氧基-4-甲基-5-氧代丙烷-2-基)氨基)-4-氧代丁酸;
英文别名：4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid;AHU-377;4-(((2S,4R)-1-([1,1\'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoic acid;ENTRESTO;
分子式：C24H29NO5
分子量：411.491
精确质量：411.205
Psa：92.7
Logp：4.2259

MDL号：MFCD00920862

可溶性：10 mM in DMSO